The Council for Innovation Promotion (C4IP) urged the Administration to maintain patent rights and not weaken them under misguided affordability strategies. C4IP submitted comments on recent Federal Trade Commission (FTC) and Department of Justice (DOJ) listening sessions regarding lowering drug prices, expressing concern that anti-patent perspectives dominated over pro-patent views. The listening sessions aimed to address various aspects related to drug pricing and competition. President Trump's Executive Orders aimed to implement measures for improving drug pricing and competition among pharmaceutical companies, emphasizing the importance of intellectual property in drug development.
The Trump Administration's efforts to lower drug prices include Executive Order 14273, which focuses on enhancing competition within the pharmaceutical market to benefit American patients.
C4IP raised concerns regarding narratives about the U.S. intellectual property system shaped by the listening sessions held by the FTC and DOJ, emphasizing the role of IP rights in drug development.
Collection
[
|
...
]